Natalie Holles has served as Chief Executive Officer of Aura Biosciences since April 2026. She has more than 25 years of executive leadership, business development, corporate strategy, and commercial experience gained in a range of therapeutic areas. Prior to Aura, Natalie served as CEO of Third Harmonic Bio from August 2021 through December 2025. Prior to Third Harmonic, Natalie served as President and Chief Executive Officer of Audentes Therapeutics (acquired by Astellas in 2020). She joined Audentes as Senior Vice President and Chief Operating Officer in August 2015 and was subsequently promoted to President and Chief Operating Officer in May 2018, and then to President and Chief Executive Officer in January 2020. Prior to joining Audentes, Natalie served as Senior Vice President, Corporate Development at Hyperion Therapeutics (acquired by Horizon Pharma in 2015). Before that, she provided executive-level strategy and business development advisory services to a number of privately held biopharmaceutical companies. Earlier in her career, Natalie served as Vice President, Business Development at KAI Pharmaceuticals (acquired by Amgen in 2012) and held corporate development and commercial roles at InterMune (acquired by Roche in 2014) and Genentech.

Natalie holds an AB in human biology from Stanford University and an MA in molecular, cellular and developmental biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute predoctoral fellow.

Tony Gibney is Chief Financial and Business Officer at Aura. Mr. Gibney is an experienced biotechnology leader and former investment banker who brings over 30 years of experience dedicated to leading and advising biotechnology companies across their businesses, including corporate strategy, business development, finance and investor relations, among others. Following his investment banking career, he has worked as Chief Business Officer at Achillion Pharmaceuticals, Inc. and Iveric Bio, Inc. and as Chief Business and Financial Officer at Fog Pharmaceuticals, Inc.

Jill Hopkins is the Chief Medical Officer and President of Research & Development at Aura. Before joining Aura, Jill served as Senior Vice President, Global Head of Ophthalmology and Exploratory Development at Novartis, and Chief Executive Officer of Gyroscope Therapeutics, a Novartis company, where she was responsible for the global ophthalmic pipeline and portfolio of medicines, gene therapy, devices and digital solutions to impact eye disease and reduce visual impairment globally. Previously, Dr. Hopkins spent over a decade at Roche-Genentech in roles of increasing responsibility, most recently as Global Head Ophthalmology Personalized Health Care. Before Roche-Genentech, she spent over 20 years in clinical retinal research and academic practice at the University of Toronto, University of Southern California, and Retina-Vitreous Associates Medical Group. Jill brings over 30 years of cross-sector experience in ophthalmology, spanning clinical care, academia, education, industry, advocacy, and innovation. Dr. Hopkins received her M.D. from McMaster University and completed her Ophthalmology residency at the University of Toronto. She has completed fellowships in Retinal Disease from Moorfields Eye Hospital in London UK and in Visual Electrophysiology from the Universities of Toronto and Ottawa. Dr. Hopkins is board certified in Ophthalmology from the American Board of Ophthalmology and the Royal College of Surgeons Canada.

Conor Kilroy is Chief Legal Officer and Secretary at Aura. Before joining Aura, Mr. Kilroy was most recently general counsel and secretary at Neurogastrx, Inc. and previously served as general counsel and secretary at Ironwood Pharmaceuticals, Inc., among other roles. Earlier in his career, Mr. Kilroy held roles at Boston Scientific Corporation and in the business law department of Goodwin Procter LLP. Mr. Kilroy holds a J.D. from Boston College Law School and a B.A. from Brandeis University.

Mark Plavsic is the Chief Technology Officer at Aura. Before joining Aura, Mark served as Chief Technology Officer at Fate Therapeutics, a clinical-stage biopharmaceutical company, and was previously Chief Technical Officer at Lysogene, a late-stage gene therapy company. Dr. Plavsic also spent over 10 years at Sanofi Genzyme in Technical Operations, where he was head of product safety and global manufacturing process improvement, and in Technology Development & Manufacturing, where he was head of gene therapy development. Before joining Sanofi Genzyme, Dr. Plavsic held various technical leadership positions with AstraZeneca, Q-One Biotech, and Life Technologies. Mark brings 30 years of global biopharmaceutical experience including end-to-end technical operations in the United States, Europe, and Australasia and successful translation and scale-up of complex biologics from preclinical development through commercial launch and distribution. Dr. Plavsic received his Ph.D. in Virology and Immunology and his DVM from the University of Belgrade, and is board certified in Microbiology, subspeciality Virology from the American College of Veterinary Microbiologists, and Regulatory Affairs Certification (RAC) credentialed.

Patrick Nealon is the Senior Vice President, Clinical Development Operations at Aura. Prior to this role, Patrick served as an Executive Vice President and General Manager, Oncology, at Syneos Health where he was responsible for the overall strategy and direction of the global clinical trials. Patrick also was responsible for the leadership of Syneos’ Clinical Pharmacology and Bioanalysis Business Unit; including two Phase I units and three global bioanalytical labs. He also previously served as the Head, Global Program Management at Servier where he led the program delivery for Shire and Baxalta. Mr. Nealon has also served in several senior leadership roles in clinical operations at Takeda Pharmaceuticals, Genzyme Corporation and ZYCOS, Inc. He received his MBA and bachelor’s degree from Anna Maria College.

Anthony Daniels is the Vice President, Therapeutic Area Head Ocular Oncology at Aura. Dr. Daniels is responsible for leading the ocular oncology program and driving future strategy. He joins Aura from Vanderbilt University Medical Center, where he was on faculty for ten years and was Chief of the Division of Ocular Oncology. Dr. Daniels is a board-certified ophthalmologist who has treated ocular oncology patients for 15 years. At Vanderbilt, in addition to his very large clinical ocular oncology practice, he ran an ocular oncology drug development laboratory as an NIH-funded physician-scientist. He received an A.B. summa cum laude in Molecular Biology from Princeton, an M.Sc. in public health and health policy from the London School of Economics and Political Science (LSE), and an M.D. from the University of Pennsylvania School of Medicine, followed by an ophthalmology residency at Harvard, a vitreoretinal surgery fellowship at Harvard, and ocular oncology training at Memorial Sloan Kettering Cancer Center, at Mayo Clinic, and at Harvard.

Joe McQuaid is Vice President, Therapeutic Area Head, Urologic Oncology at Aura Biosciences, where he is responsible for leading the urologic oncology program and driving future strategy. Dr. McQuaid is a board-certified urologic surgeon who joined Aura after serving as Associate Chief Medical Officer, Vice Chair of Urology, and Chief of the Division of Pediatric Urology at the University of Massachusetts, one of the largest academic safety net hospitals in New England.

Dr. McQuaid completed his general and urologic surgical training at the Massachusetts General Hospital and clinical and research subspecialty fellowships at Boston Children’s Hospital. He holds an MD from Harvard Medical School, an MPH from the Harvard T.H. Chan School of Public Health, an MBA from MIT Sloan School of Management, and a BA summa cum laude from the University of Pennsylvania.